Abstract
Recent data support the idea that the effects of RAS are not restricted to the cardiovascular and renal systems. Importantly, RAS modulates free radical production and the cellular synthesis of several molecules such as cytokines, chemokines and transcription factors. These functions reflect directly the RAS ability to modulate the cell growth, senescence and migration. Activation of the classic RAS, ACE/Ang II/AT1R, has been strictly related to down regulation of pro-survival genes (Nampt and Sirt3), increase in ROS production and pro-inflammatory cytokines and chemokines release, leading to cell senescence, inflammation and development of autoimmune dysfunctions. However, the new view of RAS, points to the ACE2/Ang-(1-7)/Mas receptor axis as a counter-regulator of the effects of the classic Ang II-mediated effects. This new pathway is not totally elucidated. However, some studies suggest an important role of this novel axis in the control of cytokines release as well as cell migration and synthesis, preventing extra-cellular matrix deposition and cell apoptosis. Classic RAS blockers have been proposed as anti-inflammatory and immunomodulatory agents and some studies suggest a new potential application of RAS blockers in autoimmune diseases. The aim of the present review is to update the novel roles of classical and new RAS components and their possible implication during the physiological aging, in the immune system and inflammation.
Keywords: Renin-angiotensin, aging, immune system, inflammation, Ang II, Ang-(1-7), cytokines, chemokines, transcription factors, apoptosis
Current Pharmaceutical Design
Title: Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Volume: 18 Issue: 7
Author(s): Luciano S.A. Capettini, Fabrizio Montecucco, Francois Mach, Nikos Stergiopulos, Robson A.S. Santos and Rafaela F. da Silva
Affiliation:
Keywords: Renin-angiotensin, aging, immune system, inflammation, Ang II, Ang-(1-7), cytokines, chemokines, transcription factors, apoptosis
Abstract: Recent data support the idea that the effects of RAS are not restricted to the cardiovascular and renal systems. Importantly, RAS modulates free radical production and the cellular synthesis of several molecules such as cytokines, chemokines and transcription factors. These functions reflect directly the RAS ability to modulate the cell growth, senescence and migration. Activation of the classic RAS, ACE/Ang II/AT1R, has been strictly related to down regulation of pro-survival genes (Nampt and Sirt3), increase in ROS production and pro-inflammatory cytokines and chemokines release, leading to cell senescence, inflammation and development of autoimmune dysfunctions. However, the new view of RAS, points to the ACE2/Ang-(1-7)/Mas receptor axis as a counter-regulator of the effects of the classic Ang II-mediated effects. This new pathway is not totally elucidated. However, some studies suggest an important role of this novel axis in the control of cytokines release as well as cell migration and synthesis, preventing extra-cellular matrix deposition and cell apoptosis. Classic RAS blockers have been proposed as anti-inflammatory and immunomodulatory agents and some studies suggest a new potential application of RAS blockers in autoimmune diseases. The aim of the present review is to update the novel roles of classical and new RAS components and their possible implication during the physiological aging, in the immune system and inflammation.
Export Options
About this article
Cite this article as:
S.A. Capettini Luciano, Montecucco Fabrizio, Mach Francois, Stergiopulos Nikos, A.S. Santos Robson and F. da Silva Rafaela, Role of Renin-Angiotensin System in Inflammation, Immunity and Aging, Current Pharmaceutical Design 2012; 18 (7) . https://dx.doi.org/10.2174/138161212799436593
DOI https://dx.doi.org/10.2174/138161212799436593 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allosteric Regulators of the Proteasome: Potential Drugs and a Novel Approach for Drug Design
Current Medicinal Chemistry Alopecia Areata
Recent Patents on Inflammation & Allergy Drug Discovery Immune-Regulatory Mechanisms of Classical and Experimental Multiple Sclerosis Drugs: A Special Focus on Helminth-Derived Treatments
Current Medicinal Chemistry NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer
Current Medicinal Chemistry Rheumatoid Arthritis: Conjugating Basics with Drug Delivery
Current Rheumatology Reviews Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry A New Approach to the Inflammatory/Autoimmune Diseases
Recent Patents on Anti-Infective Drug Discovery SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery Dendritic Cell-Based Therapies in the Bench and the Bedsides
Current Drug Targets - Inflammation & Allergy Tissular Senescence and Modifications of Oral Ecosystem in the Elderly: Risk Factors for Mucosal Pathologies
Current Aging Science The Role of Autophagy in Rheumatic Disease
Current Drug Targets Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Mast Cells as Target in Cancer Therapy
Current Pharmaceutical Design Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Current Topics in Medicinal Chemistry Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine